View in EDS HTML Full Text PDF Full Text

Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.

Saved in:
Bibliographic Details
Title: Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
Authors: Hall, F. (AUTHOR), de Freitas, H. M. (AUTHOR), Kerr, C. (AUTHOR), Ito, T. (AUTHOR), Nafees, B. (AUTHOR), Lloyd, A. J. (AUTHOR), Penton, J. (AUTHOR), Hadi, M. (AUTHOR), Lanar, S. (AUTHOR), Pham, T. P. (AUTHOR)
Source: Quality of Life Research. May2019, Vol. 28 Issue 5, p1191-1199. 9p. 4 Charts.
Subjects: Prostate cancer, Adverse health care events, Quality of life, Cost effectiveness, Docetaxel
Geographic Terms: United Kingdom
Abstract: Purpose: To capture UK societal health utility values for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and the disutility associated with treatment-related adverse events (AEs) to inform future cost-utility analyses.Methods: A literature review, and patient and clinical expert interviews informed the development of health states characterising mHSPC symptoms and the impact of treatment-related AEs on health-related quality of life (HRQL). Three base health states were developed describing a typical patient with high-risk mHSPC: receiving androgen deprivation therapy (ADT) [Base State 1]; receiving docetaxel plus ADT [Base State 2]; completed docetaxel and still receiving ADT whose disease has not yet progressed [Base State 3]. Six additional health states described treatment-related AEs. The health states were validated with experts and piloted with general public participants. Health state utilities were obtained using the time trade-off (TTO) method with 200 members of the UK general population. A generalised estimating equation (GEE) model was used to estimate disutility weights.Results: Mean TTO scores for Base State 1 to 3 were 0.71 (SD = 0.26), 0.64 (SD = 0.27), and 0.68 (SD = 0.26), respectively, indicating that receiving docetaxel plus ADT was most impactful on HRQL. The GEE model indicated when compared to Base State 2 that the nausea and vomiting AE had the most impact on HRQL (- 0.21), while alopecia was least burdensome (- 0.04).Conclusions: The study highlights the differences in utility between base health states and the significant impact of treatment-related AEs on the HRQL of patients with mHSPC. These findings underline the importance of accounting for impaired HRQL when assessing treatments for mHSPC. [ABSTRACT FROM AUTHOR]
Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 135927738
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Hall%2C+F%2E%22">Hall, F.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22de+Freitas%2C+H%2E+M%2E%22">de Freitas, H. M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kerr%2C+C%2E%22">Kerr, C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ito%2C+T%2E%22">Ito, T.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nafees%2C+B%2E%22">Nafees, B.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lloyd%2C+A%2E+J%2E%22">Lloyd, A. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Penton%2C+J%2E%22">Penton, J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hadi%2C+M%2E%22">Hadi, M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lanar%2C+S%2E%22">Lanar, S.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pham%2C+T%2E+P%2E%22">Pham, T. P.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Quality+of+Life+Research%22">Quality of Life Research</searchLink>. May2019, Vol. 28 Issue 5, p1191-1199. 9p. 4 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Prostate+cancer%22">Prostate cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Adverse+health+care+events%22">Adverse health care events</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+effectiveness%22">Cost effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Docetaxel%22">Docetaxel</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22United+Kingdom%22">United Kingdom</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Purpose: </bold>To capture UK societal health utility values for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and the disutility associated with treatment-related adverse events (AEs) to inform future cost-utility analyses.<bold>Methods: </bold>A literature review, and patient and clinical expert interviews informed the development of health states characterising mHSPC symptoms and the impact of treatment-related AEs on health-related quality of life (HRQL). Three base health states were developed describing a typical patient with high-risk mHSPC: receiving androgen deprivation therapy (ADT) [Base State 1]; receiving docetaxel plus ADT [Base State 2]; completed docetaxel and still receiving ADT whose disease has not yet progressed [Base State 3]. Six additional health states described treatment-related AEs. The health states were validated with experts and piloted with general public participants. Health state utilities were obtained using the time trade-off (TTO) method with 200 members of the UK general population. A generalised estimating equation (GEE) model was used to estimate disutility weights.<bold>Results: </bold>Mean TTO scores for Base State 1 to 3 were 0.71 (SD = 0.26), 0.64 (SD = 0.27), and 0.68 (SD = 0.26), respectively, indicating that receiving docetaxel plus ADT was most impactful on HRQL. The GEE model indicated when compared to Base State 2 that the nausea and vomiting AE had the most impact on HRQL (- 0.21), while alopecia was least burdensome (- 0.04).<bold>Conclusions: </bold>The study highlights the differences in utility between base health states and the significant impact of treatment-related AEs on the HRQL of patients with mHSPC. These findings underline the importance of accounting for impaired HRQL when assessing treatments for mHSPC. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=135927738
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11136-019-02117-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 1191
    Subjects:
      – SubjectFull: Prostate cancer
        Type: general
      – SubjectFull: Adverse health care events
        Type: general
      – SubjectFull: Quality of life
        Type: general
      – SubjectFull: Cost effectiveness
        Type: general
      – SubjectFull: Docetaxel
        Type: general
      – SubjectFull: United Kingdom
        Type: general
    Titles:
      – TitleFull: Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hall, F.
      – PersonEntity:
          Name:
            NameFull: de Freitas, H. M.
      – PersonEntity:
          Name:
            NameFull: Kerr, C.
      – PersonEntity:
          Name:
            NameFull: Ito, T.
      – PersonEntity:
          Name:
            NameFull: Nafees, B.
      – PersonEntity:
          Name:
            NameFull: Lloyd, A. J.
      – PersonEntity:
          Name:
            NameFull: Penton, J.
      – PersonEntity:
          Name:
            NameFull: Hadi, M.
      – PersonEntity:
          Name:
            NameFull: Lanar, S.
      – PersonEntity:
          Name:
            NameFull: Pham, T. P.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 09629343
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Quality of Life Research
              Type: main
ResultId 1